News & Media

Press release
Increased focus within Medivir’s R&D and optimizing resources through a partnership with GVK BIO

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces a reorganization within its Discovery Research department, increasing its focus within...

Read more
Press release
Medivir’s CEO increases his shareholding in the company

Stockholm, Sweden — Medivir AB (OMX: MVIR) announces that the company’s CEO, Niklas Prager, has bought 10,000 class B shares in...

Read more
Press release
Medivir’s board of directors has resolved to repurchase own shares

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announce that Medivir’s board of directors has resolved to use the authorisation...

Read more
Press release
Resolutions at the annual general meeting in Medivir on 5 May 2015

Election of the board of directors and auditorThe annual general meeting in Medivir Aktiebolag (publ) on 5 May 2015 resolved, in...

Read more
Press release
MEDIVIR AB – INTERIM REPORT JANUARY – MARCH 2015

Financial summary for the first quarterJanuary – March 2015 (2014) Net turnover totalled SEK 215.9 million (208.2 m), of which SEK...

Read more
Press release
Positive preclinical antiviral and safety profile of MIV-802 supports continued development

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announce that the preclinical antiviral and safety profile of MIV-802, Medivir’s wholly-owned...

Read more
Press release
Data from OPTIMIST trials show SVR12 rates of 97 percent in HCV patients without cirrhosis and 84 percent in HCV patients with cirrhosis

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announces that our partner Janssen Sciences Ireland UC, today publish positive results for...

Read more
Press release
OLYSIO® sales during the first quarter 2015

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announces that the global first quarter net sales of OLYSIO® (simeprevir) amounted to...

Read more
Press release
Medivir and Cancer Research Technology collaborate to develop new class of cancer drugs

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) and Cancer Research Technology (CRT), Cancer Research UK’s commercialization and development arm, today...

Read more
Press release
New simeprevir data will be presented at The International Liver Congress 2015 of the European Association for the Study of the Liver (EASL)

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that new clinical data for simeprevir, the NS3/4A protease inhibitor for...

Read more
Press release
Annual Report 2014

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Annual Report for 2014 now is available at the...

Read more
Press release
Notice of Annual General Meeting of Medivir AB (publ)

The shareholders in Medivir AB are hereby summoned to the annual general meeting on Tuesday 5 May 2015 at 2 p.m....

Read more